Difference between revisions of "Tolcher AW, et al. J. Clin. Oncol. (2012) cited as Ref 584 in DOI: 10.1038/s41392-020-0110-5 (Q9847)"
Jump to navigation
Jump to search
(Created claim: Published In Name String (P102): J. Clin. Oncol., #quickstatements; #temporary_batch_1590006349955) |
(Created claim: Page(s) (P105): 2348-2353, #quickstatements; #temporary_batch_1590074839150) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / Volume | |||
| + | 30 | ||
| Property / Volume: 30 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors (English) | ||
| Property / title: Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 2348-2353 | ||
| Property / Page(s): 2348-2353 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Tolcher AW, et al. J. Clin. Oncol. (2012) cited as Ref 584 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Tolcher AW
0 references
2012
0 references
J. Clin. Oncol.
0 references
30
0 references
Phase I study of RO4929097 a gamma secretase inhibitor of Notch signaling in patients with refractory metastatic or locally advanced solid tumors (English)
0 references
2348-2353
0 references
